Back to Search
Start Over
Letter to the Editor Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia.
- Source :
- European Journal of Haematology; Apr2004, Vol. 72 Issue 4, p302-303, 2p
- Publication Year :
- 2004
-
Abstract
- Presents letters to the editors related to the dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukemia. Principal mechanisms by which resistance to imatinib can develop; Indication on the increase of imatinib in chronic myelogenous leukemia; Inclusion of the complete hemtologic, cytogenetic and molecular remission with standard induction therapy.
Details
- Language :
- English
- ISSN :
- 09024441
- Volume :
- 72
- Issue :
- 4
- Database :
- Complementary Index
- Journal :
- European Journal of Haematology
- Publication Type :
- Academic Journal
- Accession number :
- 12460420
- Full Text :
- https://doi.org/10.1111/j.1600-0609.2004.00212.x